Albireo to Report Q3 2022 Financial Results on November 8, 2022

Rhea-AI Summary

Albireo Pharma will host a conference call and webcast on November 8, 2022, at 4:30 PM ET to discuss its financial results for the third quarter ended September 30, 2022. The call will provide a business update and review financial metrics of interest to investors.

Bylvay, Albireo’s lead product for treating pruritus in progressive familial intrahepatic cholestasis, continues to advance with ongoing Phase 3 studies in additional liver diseases.

Positive

• Bylvay is approved for PFIC, expanding treatment options for patients.
• Phase 3 trials ongoing for Alagille syndrome and biliary atresia.
• Bylvay is reimbursed in several European countries.

Negative

• None.

Conference call and webcast to be held at 4:30 pm ET

BOSTON, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that management will host a conference call and live audio webcast at 4:30 p.m. ET on November 8, 2022, to provide a business update and review the company’s financial results for the quarter ended September 30, 2022.

To access the live conference call by phone, dial 1-855-327-6837 (domestic) or 1-631-891-4304 (international), and provide the access code 10020423. A live audio webcast will be accessible from the Investors page at ir.albireopharma.com/. To ensure a timely connection to the webcast, it is recommended that participants register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will be available for replay on the Events & Presentations section of the Investors page of Albireo’s website for 3 months following the event.

About Albireo

Albireo Pharma is a rare disease company focused on the development of novel bile acid modulators to treat pediatric and adult liver diseases. Albireo’s lead product, Bylvay, was approved by the U.S. FDA as the first drug for the treatment of pruritus in all types of progressive familial intrahepatic cholestasis (PFIC), and it is also being developed to treat other rare pediatric cholestatic liver diseases with a completed Phase 3 trial in Alagille syndrome (ALGS), an ongoing Phase 3 study in biliary atresia, as well as Open-label Extension (OLE) studies for PFIC and ALGS. In Europe, Bylvay is reimbursed for the treatment of PFIC in Germany, England, Wales & Northern Ireland, Scotland, Italy, and Belgium. The Company has also completed a Phase 1 clinical trial for A3907 to advance development in adult cholestatic liver disease, with IND-enabling studies progressing with A2342 for viral and cholestatic liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. For more information on Albireo, please visit www.albireopharma.com.  

Media Contacts:
Colleen Alabiso, 857-356-3905, colleen.alabiso@albireopharma.com
Lance Buckley, 917-439-2241, lbuckley@lippetaylor.com

Investor Contact:
Hans Vitzthum, LifeSci Advisors, LLC., 617-430-7578

FAQ

When is Albireo Pharma's conference call for Q3 2022 financial results?

Albireo Pharma's conference call is scheduled for November 8, 2022, at 4:30 PM ET.

How can I access the Albireo Pharma conference call?

To access the conference call, dial 1-855-327-6837 for domestic or 1-631-891-4304 for international calls, using the access code 10020423.

What is the lead product of Albireo Pharma?

Albireo Pharma's lead product is Bylvay, approved for treating pruritus in patients with PFIC.

What are the ongoing clinical trials for Albireo Pharma?

Albireo Pharma has ongoing Phase 3 studies for Alagille syndrome and biliary atresia.

What markets are Bylvay reimbursed in?

Bylvay is reimbursed in Germany, England, Wales, Northern Ireland, Scotland, Italy, and Belgium.